Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 20/20 | 0.64 |
| ▸ | SLC16A1 | P53985 | 20/20 | 0.64 |
| ▸ | MCTS1 | Q9ULC4 | 15/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18311454 | 0.89 | SLC16A3 (0.67) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29487686 | 0.85 | SLC16A3 (0.69) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL18300792 | 0.85 | SLC16A3 (0.69) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL2225688 | 0.85 | SLC16A3 (0.59) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130371 | 0.85 | SLC16A3 (0.68) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130201 | 0.84 | SLC16A3 (0.67) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130395 | 0.83 | SLC16A3 (0.69) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130382 | 0.83 | SLC16A3 (0.51) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130255 | 0.82 | SLC16A3 (0.68) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130262 | 0.81 | SLC16A3 (0.65) | SLC16A3SLC16A1MCTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3942934-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11155522-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210009524-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2021-01-14 | — | — | US | disclosed |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-10202350-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-15 | — | — | US | disclosed |
| WO-2016201426-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155522-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-10202350-B2 | MCT4 inhibitors for treating disease | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20210009524-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.